Compared to wild-type melanoma cells, Rap1A/Rap1B expression remains unchanged upon treatment with vemurafenib, but is downregulated by combined treatment with a CYP27A1 inhibitor in vemurafenib-resistant melanoma cell lines, highlighting the potential of cholesterol metabolism in vemurafenib-resistant melanoma. Here, RAP1A is linked to melanoma.